Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Hypoxia Inducible Factor 1 Confers Androgen Independence in Prostate Cancer

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE114734 | GEO | 2019/05/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Hypoxia Inducible Factor 1 Confers Androgen Independence in Prostate Cancer

Project description:Hypoxia Inducible Factor 1 Confers Androgen Independence in Prostate Cancer

| PRJNA472393 | ENA

Altered chromatin remodeling by FOXA1 mutations promotes androgen independence and prostate cancer aggressiveness

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-11-21 | GSE128884 | GEO

Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-06-27 | GSE197781 | GEO

Dual targeting of the androgen receptor and hypoxia-inducible factor 1? pathways synergistically inhibits castration-resistant prostate cancer cells.

Project description: Not available

| S-EPMC4429716 | biostudies-literature

Hypoxia-independent downregulation of hypoxia inducible factor 1 targets by androgen deprivation therapy in prostate cancer.

Project description:Hypoxia inducible factor 1 (HIF1) has been shown to cooperate with the androgen receptor (AR) in activation of oncogenic pathways in prostate cancer (PCa). Here we hypothesized that HIF1 also plays a role in PCa response to androgen deprivation therapy (ADT). Comparison of gene expression profiles of androgen exposed (AE) and androgen deprived (AD) CWR22 PCa xenografts identified 596 upregulated and 748 downregulated genes after ADT. Gene ontology (GO) analysis of the differentially expressed genes showed significant enrichment of the biological processes cell proliferation, cell cycle and metabolism and suggested suppression of these processes after ADT. A set of 80 hypoxia-inducible genes were identified in 22Rv1 and LNCaP cell lines treated with hypoxia and showed considerable overlap (53%) with the downregulated genes. Immunostaining of the hypoxia marker pimonidazole showed no difference between AE- and AD-tumors. Comparison of the differentially expressed genes with lists of 1115 direct AR- and 276 direct HIF1-target genes identified 138 AR- and 40 HIF1-targets that were regulated after ADT, including six shared AR- and HIF1-targets for which downregulation was confirmed with RT-PCR. Most HIF1-targets were downregulated and included in the significant biological processes and the set of hypoxia-inducible genes. The downregulation of HIF1-targets was consistent with decreased HIF1A immunostaining in AD- compared to AE-tumors (p=0.002). A decrease in HIF1A immunostaining after ADT was also demonstrated in a cohort of 35 PCa patients (p<0.001). These data suggest suppressed HIF1-signaling after ADT and a shared role of HIF1 and AR in the regressive phase of PCa after ADT.

2013-10-02 | GSE42868 | GEO

Hypoxia-independent downregulation of hypoxia inducible factor 1 targets by androgen deprivation therapy in prostate cancer.

2013-10-02 | E-GEOD-42868 | biostudies-arrayexpress

Independence of HIF1a and androgen signaling pathways in prostate cancer.

Project description: Not available

| S-EPMC7249645 | biostudies-literature

Montelukast inhibits hypoxia inducible factor-1α translation in prostate cancer cells.

Project description: Not available

| S-EPMC6067895 | biostudies-other

12-Lipoxygenase and the regulation of hypoxia-inducible factor in prostate cancer cells.

Project description: Not available

| S-EPMC3420817 | biostudies-other